Company: WHWK
Filing Date: 2025-01-31
Form Type: DEFM14A
Source: 0001193125-25-018470
Chunk: 190

Company: Whitehawk Therapeutics, Inc.
Filing Date: 2025-01-31
Form: DEFM14A
Chunk 190
---
 activities, working capital and other general corporate purposes. Aadi believes the total cash and cash equivalents of Aadi following the closing of the Divestiture and PIPE Financing will enable the potential
attainment of key clinical and development milestones for the ADC Programs.

For a discussion of Aadi’s reasons for the PIPE Financing and the
License Agreement, please see the sections titled “The PIPE Financing and License Agreement—Reasons for the PIPE Financing and the License Agreement and Recommendation of the Aadi Board of Directors” beginning on page 108
of this proxy statement and “The ADC Programs” beginning on page 116 of this proxy statement.

Consequences if the PIPE Financing is Not Approved

If, for any reason, the PIPE Financing is not consummated, Aadi will not complete the issuance of common stock and
Pre-Funded Warrants pursuant to the Subscription Agreement and Aadi’s board of directors will be required to assess whether to pay the balance of the upfront license fee payment ($38 million) to WuXi Biologics under the License Agreement
by the applicable deadline with Aadi’s then-available liquidity, or otherwise to allow the License Agreement to terminate in accordance with its terms.

Required Vote

The approval of the PIPE Financing
Proposal requires the affirmative vote, in person or by proxy, of the majority of the voting power of the shares present in person or represented by proxy at the meeting and entitled to vote on the subject matter. You may vote “FOR,”
“AGAINST” or “ABSTAIN.” Broker non-votes, if any, will not be counted as entitled to vote on the subject matter for this proposal and accordingly, will have no effect on the outcome of the PIPE Financing Proposal, and abstentions
will be counted in the same manner as votes “AGAINST” the PIPE Financing Proposal.

THE AADI BOARD OF DIRECTORS RECOMMENDS A VOTE “FOR” THE PIPE FINANCING PROPOSAL

- 133 -

PROPOSAL NO. 3:

APPROVAL OF THE EQUITY PLAN INCREASE PROPOSAL

THE AADI BOARD OF DIRECTORS UNANIMOUSLY RECOMMENDS THAT AADI STOCKHOLDERS VOTE “FOR” THE EQUITY PLAN INCREASE.

Overview

We are asking our stockholders to approve the
amendment and restatement of our 2021 Plan (as amended and restated, the “Amended and Restated Plan”) to (i) increase the number of shares available for future grant under the